Search
Spotlight
CME Opportunities
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Updates in HER2+ Metastatic Breast Cancer: HER2CLIMB - Episode 1
Relapsed/Refractory HER2+ mBC: Evolving Treatment Landscape
May 18, 2020
Now Viewing
EP. 1: Relapsed/Refractory HER2+ mBC: Evolving Treatment Landscape
EP. 2: Exciting Results From HER2CLIMB in HER2+ mBC
EP. 3: HER2CLIMB: Implications for Brain Metastases in HER2+ mBC
EP. 4: HER2+ mBC: Safety and Tolerability in HER2CLIMB
EP. 5: Personal Experience With the HER2CLIMB Regimen in mBC
EP. 6: HER2CLIMB: Sequencing in Metastatic Breast Cancer
EP. 7: Relapsed/Refractory HER2+ mBC: Future Treatment Landscape
Related Content:
Updates in HER2+ Metastatic Breast Cancer: HER2CLIMB
HER2+ Breast Cancer
Breast Cancer
Oncology Business Management
postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer
Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer
Five Under 5: Top Oncology Videos for the Week of 5/11
x